<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432019000200061</article-id>
<article-id pub-id-type="doi">10.7399/fh.11133</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Optic neuropathy associated with linezolid: systematic review of cases]]></article-title>
<article-title xml:lang="es"><![CDATA[Neuropatía óptica asociada a linezolid: revisión sistemática de casos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Brandariz-Núñez]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Corredoira]]></surname>
<given-names><![CDATA[Virginia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guarc-Prades]]></surname>
<given-names><![CDATA[Eva]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Navarro]]></surname>
<given-names><![CDATA[Bárbara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Quironsalud Barcelona Pharmacy Unit ]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<volume>43</volume>
<numero>2</numero>
<fpage>61</fpage>
<lpage>65</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432019000200061&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432019000200061&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432019000200061&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: Collect and analyze all the described cases of optic neuropathy associated with linezolid.  Method: A systematic review of cases was carried out through a search in PubMed-Medline, Embase and ScienceDirect, between September 2002 and April 2018. The demographic, clinical and ophthalmology characteristics of each patient were evaluated.  Results: A total of 33 cases from 26 independent articles were analyzed. The mean age was 44.97 ± 21.40 years (range: 6-79) and 16 (50%) of 32 cases were women. The duration of treatment with linezolid until onset of symptoms was greater than 28 days in 29 (90.6%) of 32 documented cases. The mean time of exposure to onset of symptoms was 8.5 ± 8.6 months (range: 0.33-50). A total of 12 of 26 adult patients received linezolid 600 mg/24 h, starting. In 30 (90.9%) patients loss of visual acuity was documented. Linezolid was withdrawn in all cases once the diagnosis was confirmed, with clinical improvement in 31 (93.9%) cases.  Conclusions: Optic neuropathy is a reversible complication related to the prolonged use of linezolid and regardless of the dose. We recommend follow-up in patients with long treatments (&gt; 28 days) and ophthalmological exploration in those with visual alterations for the early diagnosis of neuropathy and early withdrawal of linezolid.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Recoger y analizar todos los casos descritos de neuropatía óptica asociada a linezolid.  Método: Se realizó una revisión sistemática de casos mediante una búsqueda en PubMed-Medline, Embase y ScienceDirect, entre septiembre de 2002 y abril de 2018. Se evaluaron las características demográficas, clínicas y oftalmológicas de cada paciente.  Resultados: Se analizaron un total de 33 casos procedentes de 26 artículos independientes. La media de edad fue de 44,97 ± 21,40 años (rango: 6-79) y 16 (50%) de los 32 casos fueron mujeres. La duración del tratamiento con linezolid hasta el comienzo de los síntomas fue superior a 28 días en 29 (90,6%) de los 32 casos documentados. El tiempo medio de exposición hasta el comienzo de los síntomas fue de 8,5 ± 8,6 meses (rango: 0,33-50). Un total de 12 de 26 pacientes adultos recibieron linezolid 600 mg/24 h de inicio. En 30 (90,9%) pacientes se documentó pérdida de la agudeza visual. Se retiró linezolid en todos los casos una vez confirmado el diagnóstico, con mejoría clínica en 31 (93,9%) casos.  Conclusiones: La neuropatía óptica es una complicación reversible relacionada con el uso prolongado de linezolid e independiente de la dosis. Recomendamos realizar un seguimiento a los pacientes con tratamientos largos (&gt; 28 días) y exploración oftalmológica en aquellos con alteraciones visuales para el diagnóstico temprano de la neuropatía y la retirada precoz de linezolid.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Linezolid]]></kwd>
<kwd lng="en"><![CDATA[Multidrug resistant tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[Optic neuropathy]]></kwd>
<kwd lng="en"><![CDATA[Oxazolidinones]]></kwd>
<kwd lng="en"><![CDATA[Side effects]]></kwd>
<kwd lng="es"><![CDATA[Efectos adversos]]></kwd>
<kwd lng="es"><![CDATA[Linezolid]]></kwd>
<kwd lng="es"><![CDATA[Neuropatía óptica]]></kwd>
<kwd lng="es"><![CDATA[Oxazolidinonas]]></kwd>
<kwd lng="es"><![CDATA[Tuberculosis multirresistente]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stalker]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jungbluth]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical pharmacokinetics of linezolid, a novel oxazolidinona antibacterial]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2003</year>
<volume>42</volume>
<page-range>1129-40</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series]]></article-title>
<source><![CDATA[Diagn Microbiol Infect Dis]]></source>
<year>2007</year>
<volume>59</volume>
<page-range>173-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schecter]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[True]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Raftery]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Flood]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mase]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid in the treatment of multidrug-resistant tuberculosis]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2010</year>
<volume>50</volume>
<page-range>49-55</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glaser]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nutritional and toxic optic neuropathies]]></article-title>
<source><![CDATA[Neuro-Ophthalmology]]></source>
<year>1999</year>
<edition>3a ed</edition>
<page-range>181-6</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Lippincott Williams and Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Javaheri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khurana]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;hearn]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Sadun]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid induced optic neuropathy: a mitocondria disorder?]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2007</year>
<volume>91</volume>
<page-range>111-5</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grzybowski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zulsdorff]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wilhelm]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tonagel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxic optic neuropathies: An updated review]]></article-title>
<source><![CDATA[Acta Ophthalmol]]></source>
<year>2015</year>
<volume>93</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>402-10</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schecter]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[True]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Raftery]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Flood]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mase]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid in the Treatment of Multidrug-Resistant Tuberculosis]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2010</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>49-55</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Udwadia]]></surname>
<given-names><![CDATA[ZF]]></given-names>
</name>
<name>
<surname><![CDATA[Sen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Moharil]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of linezolid efficacy and safety in MDRand XDR-TB: an Indian perspective]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2010</year>
<volume>35</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>936-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Isaakidis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Andries]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mansoor]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Meintjes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid for multidrug-resistant tuberculosis in HIV-infected and uninfected patients]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2015</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>271-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sotgiu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Centis]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Ambrosio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Alffenaar]]></surname>
<given-names><![CDATA[JWC]]></given-names>
</name>
<name>
<surname><![CDATA[Anger]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Caminero]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2012</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1430-42</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Falagas]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Vardakas]]></surname>
<given-names><![CDATA[KZ]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis]]></article-title>
<source><![CDATA[J Thorac Dis]]></source>
<year>2015</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>603-15</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Burger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Melton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mullen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-associated toxic optic neuropathy: a report of 2 cases]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2003</year>
<volume>37</volume>
<page-range>1389-91</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frippiat]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bergiers]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Michel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dujardin]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Derue]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe bilateral optic neuritis associated with prolonged linezolid therapy]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2004</year>
<volume>53</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1114-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mckinley]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Foroozan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optic Neuropathy Associated with Linezolid Treatment]]></article-title>
<source><![CDATA[J Neuroophthalmol]]></source>
<year>2005</year>
<volume>25</volume>
<page-range>18-21</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saijo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yamada]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wakakura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-induced optic neuropathy]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2005</year>
<volume>139</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1114-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kulkarni]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Del Priore]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid induced toxic optic neuropathy]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2005</year>
<volume>89</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1664-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azamfirei]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Copotoiu]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Branzaniuc]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Szederjesi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Copotoiu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Berteanu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complete blindness after optic neuropathy induced by short-term linezolid treatment in a patient suffering from muscle dystrophy]]></article-title>
<source><![CDATA[Pharmacoepidemiol Drug Saf]]></source>
<year>2007</year>
<volume>16</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>402-4</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiuchi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Miyashiro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kitagawa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wada]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-associated optic neuropathy in a patient with ocular sarcoidosis]]></article-title>
<source><![CDATA[Jpn J Ophthalmol]]></source>
<year>2009</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>420-4</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karuppannasamy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Raghuram]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sundar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-induced optic neuropathy]]></article-title>
<source><![CDATA[Indian J Ophthalmol]]></source>
<year>2014</year>
<volume>62</volume>
<page-range>497-500</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khadilkar]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Yadav]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Rajan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid Optic Neuropathy: Be Careful and Quick]]></article-title>
<source><![CDATA[J Assoc Physicians India]]></source>
<year>2013</year>
<volume>61</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>866-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaitali]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Suresh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comment on linezolid induced optic neuropathy]]></article-title>
<source><![CDATA[Indian J Ophthalmol]]></source>
<year>2015</year>
<volume>63</volume>
<page-range>75-6</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agrawal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Addison]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Saihan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Pefkianaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pavesio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optic neuropathy secondary to linezolid for multidrug-resistant mycobacterial spinal tuberculosis]]></article-title>
<source><![CDATA[Ocul Immunol Inflamm]]></source>
<year>2015</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>90-2</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[Ohn]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid induced retinopathy]]></article-title>
<source><![CDATA[Doc Ophthalmol]]></source>
<year>2015</year>
<volume>131</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>237-44</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ishii]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kinouchi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-induced optic neuropathy with a rare pathological change in the inner retina]]></article-title>
<source><![CDATA[Int Ophthalmol]]></source>
<year>2016</year>
<volume>36</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>761-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez Prats]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Llinares Tello]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Climent Grana]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez Aracil]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Peripheral and optic neuropathy associated to linezolid in multidrug resistant Mycobacterium bovis infection]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2005</year>
<volume>124</volume>
<page-range>797-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rhiu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-associated optic neuropathy in a patient with drug-resistant tuberculosis]]></article-title>
<source><![CDATA[J Neuroophthalmol]]></source>
<year>2013</year>
<volume>33</volume>
<page-range>316-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eisenack]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Landau]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wildberger]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Knecht]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-associated optic neuropathy?]]></article-title>
<source><![CDATA[Klin Monbl Augenheilkd]]></source>
<year>2012</year>
<volume>229</volume>
<page-range>433-4</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xerri]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Lemaire]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Nasser]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rousseau-Huvey]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Labetoulle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rousseau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropathie optique toxique grave liee au linezolide]]></article-title>
<source><![CDATA[J Fr Ophtalmol]]></source>
<year>2015</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>55-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[SRJ]]></given-names>
</name>
<name>
<surname><![CDATA[Large]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Yacoub]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lightman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Case of Optic Neuropathy after Short-Term Linezolid Use in a Patient with Acute Lymphocytic Leukemia]]></article-title>
<source><![CDATA[Clin Infect Dis (Internet)]]></source>
<year>2009</year>
<volume>48</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>73-4</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenzweig]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Yancoski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bernasconi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Krasovec]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marciano]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Casimir]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thirteen years of culture-positive M. bovis-BCG infection in an IL-12Rs1 deficient patient: Treatment and outcome]]></article-title>
<source><![CDATA[J Infect]]></source>
<year>2006</year>
<volume>52</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>10-3</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rucker]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Bardenstein]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Isada]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid associated toxic optic neuropathy]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2006</year>
<volume>66</volume>
<page-range>595-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Vriese]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coster]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Smet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Seneca]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lowering]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Van Haute]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis]]></article-title>
<source><![CDATA[Clin Infest Dis]]></source>
<year>2006</year>
<volume>42</volume>
<page-range>1111-7</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corallo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Paull]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-induced neuropathy]]></article-title>
<source><![CDATA[Med J Aust]]></source>
<year>2002</year>
<volume>177</volume>
<page-range>332</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Srivastava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kshetrimayum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Kant]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-induced optic neuropathy in XDR pulmonary TB: A case series]]></article-title>
<source><![CDATA[Indian J Tuberc]]></source>
<year>2017</year>
<volume>64</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>129-33</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez Saldana]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Galvis Trujillo]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Borbolla Pertierra]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Mondragon Pineda]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Juarez Olguin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolid-associated optic neuropathy in a pediatric patient with Mycobacterium nonchromogenicum: A case report]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2017</year>
<volume>96</volume>
<numero>50</numero>
<issue>50</issue>
</nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kreps]]></surname>
<given-names><![CDATA[EO]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rennie]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical recovery in linezolid-induced optic nerve toxicity]]></article-title>
<source><![CDATA[Acta Ophthalmol]]></source>
<year>2017</year>
<volume>95</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>341-2</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Laxmeshwar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jonckheere]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Thi]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Isaakidis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linezolidassociated optic neuropathy in drug-resistant tuberculosis patients in Mumbai, India]]></article-title>
<source><![CDATA[PLoS One (Internet)]]></source>
<year>2016</year>
<volume>11</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bressler]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmer]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Gilmore]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Somani]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Peripheral neuropathy associated with prolonged use of linezolid]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2004</year>
<volume>4</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>528-31</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
